PUX7 Antibody

What is the relationship between P2X7 and PUX7 antibodies?

P2X7 is a well-documented purinergic receptor studied extensively in immunology, while "PUX7" appears to be primarily a commercial product designation rather than a standard scientific nomenclature. The scientific literature predominantly references P2X7 antibodies for research applications in detecting the P2X7 receptor, which functions as an ATP-gated cation channel expressed on various immune cells . When evaluating antibody products labeled as "PUX7," researchers should carefully verify the target antigen specificity to determine if these actually target the P2X7 receptor or a different protein entirely.

What detection challenges exist when using antibodies against P2X7?

Research indicates a notable dichotomy in P2X7 antibody performance based on protein conformation. Antibodies raised against synthetic P2X7 peptides generally perform well in Western blot analyses (detecting denatured protein) but frequently fail to recognize the native protein on the cell surface . This conformation-dependent recognition challenge necessitates careful antibody selection based on the intended application:

Researchers should validate any P2X7 antibody thoroughly with appropriate negative controls before proceeding with experiments requiring native protein detection.

Why is genetic immunization preferred for developing P2X7 antibodies?

Genetic immunization has emerged as a superior technique for generating antibodies that effectively recognize native P2X7 receptor configurations. This approach involves immunizing animals with DNA encoding the P2X7 protein rather than synthetic peptides or recombinant proteins . The advantages include:

• Expression of the protein in its native conformation within the animal

• Proper post-translational modifications

• Superior recognition of the target in its physiological membrane environment

• Improved performance in flow cytometry and live-cell applications

Using this technique, researchers have successfully generated highly specific polyclonal (rabbit) and monoclonal (rat) anti-P2X7 antibodies that effectively detect mouse P2X7 on living cells by immunofluorescence analyses and flow cytometry .

How do ATP-induced conformational changes affect P2X7 antibody binding?

Experimental evidence reveals a fascinating phenomenon: P2X7 antibody binding is rapidly reduced within seconds after ATP treatment of cells . This observation suggests two possible mechanisms:

• Conformational shift hypothesis: ATP binding induces structural reorganization of the P2X7 receptor, potentially masking antibody epitopes

• Shedding hypothesis: ATP stimulation triggers the release of P2X7 from the cell surface

Methodological approach to investigate this phenomenon:

• Pre-label cells with fluorescently tagged P2X7 antibodies

• Record baseline binding by flow cytometry or live-cell imaging

• Add ATP at physiological concentrations (1-5 mM)

• Monitor fluorescence intensity changes over time (0-60 seconds)

• Compare with fixed cells to differentiate between shedding and conformational changes

This receptor conformational dynamism has significant implications for experimental design, particularly when using antibodies to quantify receptor density after ATP exposure.

What insights do P2X7 mutation studies provide about critical functional domains?

Site-directed mutagenesis experiments targeting conserved arginine residues (R294A, R307A, R316A) in the extracellular loop of P2X7 near the second transmembrane region have revealed essential functional insights . Each of these mutations results in loss of ATP response, indicating these residues are critical for ligand recognition or channel function.

Flow cytometry and immunoblot analyses demonstrate that the R294A mutant is expressed at higher levels than wild-type P2X7 in transfected cells, whereas the R307A and R316A mutants show dramatically reduced expression . This suggests that these arginine residues play dual roles in both receptor function and protein stability/trafficking.

Researchers investigating P2X7 function should consider:

• Using these mutations as experimental controls

• Designing antibodies that specifically recognize these critical regions

• Employing epitope mapping to ensure antibodies don't interfere with functional domains

How does P2X7 contribute to graft-versus-host disease pathophysiology?

Recent research using species-specific blocking monoclonal antibodies (mAb) against human P2X7 has provided direct evidence for donor P2X7's role in graft-versus-host disease (GVHD) . In a humanized mouse model:

• NOD-scid IL2Rγ null mice were injected with human peripheral blood mononuclear cells

• Anti-human P2X7 or control mAb was administered (100 μg i.p. per mouse) on days 0, 2, 4, 6, and 8

• The anti-human P2X7 mAb treatment significantly:

  • Increased human regulatory T cells (hTregs) and human natural killer (hNK) cells

  • Reduced clinical and histological GVHD in the liver and lung

  • Increased hTregs, hNK, and hNK T cell proportions

  • Decreased human T helper 17 cell proportions

These findings demonstrate that selective blockade of donor P2X7 reduces GVHD development, presenting a potential therapeutic approach targeting this pathway.

What methodological considerations are essential when validating P2X7 antibodies?

Comprehensive validation of P2X7 antibodies requires a multi-faceted approach:

• Cross-species reactivity testing: P2X7 shows significant species variation, making it critical to validate each antibody for the specific species under investigation

• Conformation-specific validation: Test the antibody against both native and denatured forms using:

  • Western blotting (denatured)

  • Flow cytometry (native)

  • Immunoprecipitation (native)

• Functional assessment: Determine if antibody binding affects receptor function by measuring:

  • ATP-induced pore formation

  • Calcium influx

  • NLRP3 inflammasome activation

• Specificity controls:

  • Use P2X7 knockout cells/tissues

  • Employ P2X7 antagonists to confirm specificity

  • Test against related P2X family members

• Epitope location consideration: Antibodies recognizing different epitopes may yield contradictory results depending on:

  • Splice variant expression

  • Post-translational modifications

  • Protein-protein interactions

How can researchers leverage P2X7 antibodies to study interactions with the autophagy system?

Recent research indicates potential connections between P2X7 signaling and autophagy pathways, particularly through ATG8/LC3 interactions . While not directly studied with P2X7 antibodies, this represents an emerging research area where antibody-based approaches could provide valuable insights.

Experimental design considerations:

• Use P2X7 antibodies in combination with autophagy markers (LC3, p62/SQSTM1)

• Investigate whether P2X7 activation modulates autophagy flux

• Examine potential co-localization between P2X7 and autophagy-related structures

• Explore whether P2X7 interacts with either conventional ATG8-interacting motif (AIM) or the newly identified ubiquitin-interacting motif (UIM) pathways

This approach could reveal novel connections between purinergic signaling and selective autophagy in immune regulation.

What controls are essential when using P2X7 antibodies in multi-color flow cytometry?

When incorporating P2X7 antibodies into complex flow cytometry panels, researchers should implement these critical controls:

• Fluorescence minus one (FMO): Particularly important as P2X7 expression can be subtle on some cell populations

• ATP stimulation control: Include samples with brief ATP exposure to demonstrate functional P2X7 expression through:

  • Increased membrane permeability to viability dyes

  • Calcium flux detected with indo-1 or fluo-4

  • Surface marker shedding (CD62L)

• Competitive binding control: Pre-block with unlabeled antibody to verify specificity

• Species-matched isotype control: Essential when examining tissues with high Fc receptor expression

• Fixation/permeabilization impact assessment: Test how preparation affects epitope recognition

A carefully designed panel might include P2X7 alongside markers for:

• T cell subsets (CD3, CD4, CD8)

• Regulatory T cells (CD25, FOXP3)

• Natural killer cells (CD56, CD16)

• Natural killer T cells (CD3, CD56)

• T helper 17 cells (CCR6, IL-23R)

How should researchers approach troubleshooting when P2X7 antibodies yield contradictory results?

When different P2X7 antibody-based methods produce conflicting data, implement this systematic troubleshooting approach:

• Epitope accessibility analysis:

  • Map the epitopes recognized by each antibody

  • Consider whether protein conformation, post-translational modifications, or protein-protein interactions might differentially affect epitope exposure

• Sample preparation comparison:

  • Test multiple fixation/permeabilization protocols

  • Compare fresh versus frozen samples

  • Evaluate different detergents for protein extraction

• Receptor activation state consideration:

  • Pre-treat samples with P2X7 agonists (ATP) or antagonists

  • Test samples at different time points after stimulation

• Validation with orthogonal methods:

  • Confirm protein expression with PCR

  • Use reporter systems (e.g., GFP-tagged P2X7)

  • Employ functional assays (ethidium uptake, calcium influx)

• Receptor variant analysis:

  • Sequence the P2X7 gene to identify potential variants

  • Use variant-specific primers or antibodies if available

What cell types benefit most from P2X7 antibody-based detection methods?

P2X7 antibody applications provide different advantages depending on the cell type and context:

Research demonstrates that P2X7 expression on regulatory T cells, natural killer cells, and natural killer T cells is particularly significant in contexts like graft-versus-host disease, where antibody-mediated receptor blockade increases these cell populations and reduces pathology .

How can researchers leverage P2X7 antibodies to develop new therapeutic approaches?

The development of species-specific blocking monoclonal antibodies against P2X7 has opened new therapeutic possibilities beyond small molecule inhibitors. Key research strategies include:

• Humanized model testing: The proven efficacy of anti-human P2X7 mAb in reducing GVHD in humanized mice provides a foundation for translational studies

• Cellular subset targeting: Research indicates P2X7 blockade selectively affects inflammatory T cell subsets while preserving or enhancing regulatory and NK cell populations

• Combination therapy evaluation: Investigate P2X7 antibody efficacy when combined with:

  • Post-transplant cyclophosphamide

  • JAK inhibitors

  • IL-6 blockade

  • Regulatory T cell therapy

• Biomarker identification: Use P2X7 antibodies to identify patient subgroups likely to benefit from P2X7-targeted therapy

• Alternative antibody formats: Explore:

  • Bispecific antibodies targeting P2X7 and inflammatory mediators

  • Antibody-drug conjugates for selective cell targeting

  • Single-chain variable fragments with improved tissue penetration

The evidence that blockade of human (donor) P2X7 reduces GVHD development in humanized mice provides direct support for pursuing this therapeutic avenue in clinical settings .